Pfizer and BioNTech Agree to Vaccine Technology Transfer with South Africa s Biovac Institute
As reported by Reuters on Wednesday (
e ), Pfizer and BioNTech, manufacturers and developers of an mRNA-based vaccine against SARS-CoV-2, have agreed to help the South African drug maker Biovac Institute produce about 100 million doses per year of its vaccine, specifically to be targeted to African nations.
As described by the Reuters article, Biovac Institute is a joint venture between the South African government and private sector partners ; it has an advantage as being the first company in Africa to use mRNA technology to make the vaccine. The scope of the cooperative agreement is limited to fill and finish aspects of the vaccine, leaving Pfizer and BioNTech to produce the mRNA components of the vaccine in Europe (for a more detailed description of the vaccine making process,
Hope for African Countries as South Africa plans to start producing Pfizer/BioNTech COVID-19 vaccine
hapakenya.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hapakenya.com Daily Mail and Mail on Sunday newspapers.
Watch our Covid-19 weekly round-up: SA secures enough vaccines for the rest of the year
iol.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iol.co.za Daily Mail and Mail on Sunday newspapers.
AP Story
talkradio1170.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from talkradio1170.com Daily Mail and Mail on Sunday newspapers.